Roche Beats Rivals To Japan Tumor-Agnostic Market With World-First Rozlytrek Nod

 
• By Ian Haydock

Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over its rival in this market. But sales may be limited.

Cancer - DNA - test tube
Japan Nod For Rozlytrek In Specific Tumor Type • Source: Shutterstock

More from Japan

More from Focus On Asia